Korean drug makers get a win in generic Lipitor case

Recently, a local Patent Trial Board ruled that a key patent that Pfizer holds on atorvastatin, the active ingredient in Lipitor, is invalid. The decision means that Pfizer's Korean patent on the drug, the world's top-selling prescription branded medication, is no longer viable.

The patent challenge had been brought by five Korean generic drug makers.

In response, Pfizer Korea expressed d...